Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.

Subjects

Subjects :

THERAPEUTIC use of antimetabolites
CISPLATIN
CANCER relapse
RESEARCH funding
ANTIMETABOLITES
STATISTICAL sampling
TREATMENT effectiveness
RANDOMIZED controlled trials
DESCRIPTIVE statistics
TREATMENT duration
METASTASIS
CANCER chemotherapy
DOSE-response relationship in biochemistry
GEMCITABINE
DRUG efficacy
PACLITAXEL
NASOPHARYNX cancer
COMPARATIVE studies
PROGRESSION-free survival
CONFIDENCE intervals
SURVIVAL analysis (Biometry)
EVALUATION

Details

Language :

English

ISSN :

17561833

Volume :

385

Issue :

8433

Database :

Complementary Index

Journal :

BMJ: British Medical Journal

Publication Type :

Academic Journal

Accession number :

178237107

Full Text :

https://doi.org/10.1136/bmj-2023-077890